Phathom outlines $320M-$345M 2026 revenue as it targets operating profitability by Q3
Source: SeekingAlpha
2026-04-30 15:32:56 ET
More on Phathom Pharmaceuticals
- Phathom Pharmaceuticals, Inc. (PHAT) Q1 2026 Earnings Call Transcript
- Phathom Pharmaceuticals, Inc. (PHAT) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
- Phathom Pharmaceuticals, Inc. 2025 Q4 - Results - Earnings Call Presentation
- Phathom Pharmaceuticals gives mixed Q1 results
- Phathom Pharmaceuticals Q1 2026 Earnings Preview
Read the full article on Seeking Alpha
For further details see:
Phathom outlines $320M-$345M 2026 revenue as it targets operating profitability by Q3
Phathom Pharmaceuticals Inc.
NASDAQ: PHAT
PHAT Trading
-2.51% G/L:
$10.675 Last:
406,129 Volume:
$10.90 Open:
PHAT Latest News
June 23, 2026 07:59:00 am
Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)
May 20, 2026 08:00:00 am
Phathom Pharmaceuticals Highlights Breadth of Independent Vonoprazan Research at Digestive Disease Week 2026 Annual Meeting
May 01, 2026 08:00:00 am
Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at DDW 2026 Annual Meeting
$1,007,653,754
60,286,977
0.48%
62
N/A
Biotechnology & Life Sciences
Healthcare
US
Florham Park
